$2.22
$34.14
52-Week Range
At a Glance
AI-generatedGalecto, Inc.
8-K
Damora Therapeutics, Inc. appointed Jennifer Jarrett as President and Chief Executive Officer effective March 30, 2026, succeeding Sherwin Sattarzadeh who continues as COO, and appointed Michael Landsittel and Cameron Turtle as Class III directors effective March 23, 2026. Three directors resigned, Peter Harwin became Board Chair, and Garrett Winslow received a new offer letter as General Counsel.$40M
Market Cap
—
Revenue
-$210M
Net Income
Employees5
Fundamentals
How The Business Makes Money
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001800315
ISINUS36322Q2066
CUSIP36322Q107
Phone457 070 5210
Address75 State Street, Boston, MA, 02109, US
SEC EDGAR